▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #20 by analyst upside · 2026-09-27
SKYE
Skye Bioscience, Inc.
Healthcare · Market Cap $7M · P/E 0x
ANALYST PRICE TARGET
+3971.9%
implied upside to consensus target
Current Price $1.67
Consensus Target $68.0
Bull Target $160.0
Bear Target $16.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
2
Sell
0
52-Week Low $1.5
52-Week High $39.92
YTD Return -76.2%
FUNDAMENTALS
Market Cap $7M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-10.24
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.5
52-Week High $39.92
Current Price $1.67
Bear Target $16.0
Bull Target $160.0
● Now $1.67 ● Target $68.0
TRADING DATA
Avg Volume 87K
YTD Return -76.2%
Analyst Count 4
Consensus Buy
Upside to Target +3971.9%
Last Updated 2026-09-27

ANALYST SUMMARY

Skye Bioscience, Inc. (SKYE) is currently trading at $1.67 with a Wall Street consensus price target of $68.0, implying potential upside of 3971.9% over the next 12 months. 4 analysts currently cover SKYE, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $160.0, while the most cautious has a target of $16.0.

SKYE operates in the Healthcare sector with a market capitalisation of $7M. The stock is down 76.2% year-to-date and is currently trading near the lower end of its 52-week range of $1.5 – $39.92.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRIS +5041.2%
Curis, Inc.
$2M · P/E 0.2x · Buy
CNSY +1533.2%
Cerenome, Inc.
$15M · P/E 0.7x · Buy
TOVX +1033.3%
Theriva Biologics, Inc.
$10M · P/E 0.2x · Strong Buy
GTBP +988.5%
GT Biopharma, Inc.
$12M · P/E 0.1x · Buy
ETST +974.6%
Earth Science Tech, Inc.
$27M · P/E 9.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for SKYE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2025-09-30 31% win rate (48 calls)
Evercore ISI Group ● Initiated
Outperform 2025-08-15 Building track record
JMP Securities reit
Market Outperform → Market Outperform 2025-06-24 Building track record
Craig-Hallum - Reiterated
Buy → Buy 2025-03-21 Building track record
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-03-21 Building track record
William Blair ● Initiated
Outperform 2025-02-28 44% win rate (9 calls)
Scotiabank ● Initiated
Sector Outperform 2024-09-30 20% win rate (5 calls)
Piper Sandler reit
Overweight → Overweight 2024-09-20 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
19
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →